T3Inh-1

Research use only, not for human use.

T3Inh-1 is an effective and selective inhibitor of ppGalNAc-T3 with an IC50 of 7 μM. T3Inh-1 prevents breast cancer cells. T3Inh-1 reduces FGF23 hormone levels in both tissue cells and mice, without causing any toxic side effects.

T3Inh-1 is an effective and selective inhibitor of ppGalNAc-T3 with an IC50 of 7 μM. T3Inh-1 prevents breast cancer cells. T3Inh-1 reduces FGF23 hormone levels in both tissue cells and mice, without causing any toxic side effects. (In Vitro):In HEK cells, T3Inh-1 (6h)increased the cleavage of FGF23. In MDA-MB231 cells, T3Inh-1(5 μM; 24h, 48h) inhibited migration by >80% and invasion by 98% while causing no discernable effect on cell proliferation. T3Inh-1 exhibited no toxicity and did not affect HEK cell proliferation.(In Vivo):In Wild-type C57BL/6 mice, T3Inh-1 (25, 50 mg/kg; i.p.) blocked ppGalNAc-T3-mediated glycan-masking of FGF23 and increased its cleavage.

T3Inh-1 (5 μM; 24-48 hours; 5 μM; MDA-MB231 cells) is strikingly effective, inhibiting migration by >80% and invasion by 98% while causing no discernable effect on cell proliferation.T3Inh-1 exhibits no toxicity and did not affect HEK cell proliferation.T3Inh-1 (HEK cells; 6 hours)increases cleavage of FGF23.

T3Inh-1 (25 or 50 mg/kg; i.p.) blocks ppGalNAc-T3-mediated glycan-masking of FGF23 thereby increasing its cleavage. Animal Model:Wild-type C57BL/6 six to eight week old mice Dosage:25 or 50 mg/kg Administration: Intraperitoneal injection (Dissolved in DMSO at 25 and 50 mg/ml then further diluted with PEG400 to create 5 and 10 mg/ml stocks for injection)Result:Caused a robust and statistically significant increase the ratio of cleaved/intact FGF23 at the tested 25 and 50 mg/kg concentrations.

——

Others

Other Targets

5-HT3

——

——

50440-30-7

476.49

C27H20N6O3

>98% (HPLC)

In Vitro:?DMSO : 10 mg/mL (20.99 mMul)

[O-][N+](c(ccc1ncc2)cc1c2Nc(cc1)ccc1C(Nc(cc1)ccc1Nc1ccncc1)=O)=O

——

(-20℃)

With Ice Pack

≥ 2 years